Grifols Therapeutics LLC
Nasdaq GRFS · New York, NY
Works in Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Respiratory
Grifols Therapeutics LLC is a clinical trial sponsor based in New York, NY, listed as Nasdaq GRFS. It has 4 active clinical trials with 756 planned participants, across 9 therapeutic areas. Since 2021 it has completed 10 trials and stopped 4 early.
Trial track record · since 2021
Financials · Nasdaq GRFS
Pipeline · 4 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Grifols Therapeutics LLC
Grifols Therapeutics LLC is lead sponsor of 4 active clinical trials on ClinicalTrials.gov, with 756 planned participants, in Genetic & rare, GI & liver, Hematology, Immunology and other areas. Since 2021 it has completed 10 trials and stopped 4 early.
Grifols Therapeutics LLC is based in New York, NY and is listed as Nasdaq GRFS. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Grifols Therapeutics LLC; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-26.
Approve Suite is not affiliated with Grifols Therapeutics LLC.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.